Chimfwembe EC, Stahli C, Mukunyandela M; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 310 (abstract no. T.B.P.144).
Tropical Diseases Research Centre, Ndola, Zambia
OBJECTIVE: The availability of various anti HIV commercial kits and the concern for valid results calls for the establishment of a panel of well defined sera for evaluation of test kits. For quality control purposes, a panel of sera was assayed for anti HIV using various kits in two laboratories. METHODS: Sera from 17 adult Zambian patients suspected to have AIDS were tested at Ndola, Zambia and Basle, Switzerland, for anti HIV. The following kits were used; Wellcozyme VK50/51 (Wellcome), Enzygnost-micro (Behring), Roche and HIV EIA and the Western Blot (W.B.). An assay used to investigate the presence of peroxidase inhibitors, suggested by the Wellcome Research and Development Laboratory, was performed as a check on the Wellcozyme. RESULTS: Thirteen out of the 17 sera produced the same results in both laboratories on all the kits. The remaining 4 were repeatedly positive on the Wellcozyme in Ndola but negative in Basle, and negative on all other test kits including the confirmatory test (W.B.) in both laboratories. COMMENTS AND CONCLUSION: The difference in results of the 4 sera may be due to (a) the presence of factors in sera that inhibit the peroxidase conjugate or (b) batch to batch variation of the peroxidase conjugate. It is suggested that (1) such discrepancies in results from biological kits may occur and require both internal and external quality control; (2) laboratories have a panel of well defined sera for the evaluation and monitoring of batch to batch variation of kits and reagents.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Adult
- Blotting, Western
- Evaluation Studies
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Infections
- HIV Seropositivity
- Humans
- Immunoenzyme Techniques
- Mass Screening
- Switzerland
- Zambia
- immunology
Other ID:
UI: 102177382
From Meeting Abstracts